Giuliana Grossi

Greg Marchand has achieved world records in the field of OBGYN and minimally invasive surgery. In an interview, he discusses the progress of the outpatient hysteroscopy.

Investigators developed the first module to confront implicit bias toward patients with sickle cell disease on an individual or personal level.

The American Society of Hematology debuted its Health Equity Rounds series, which are interactive, case-based discussions with an interdisciplinary panel to include hematologists, health equity/public health experts, patients, and patient advocates.

The clinical program has been suspended for patients that are under the age of 18 after an adolescent patient developed persistent anemia.

Fuad El Rassi talks about the Grady Comprehensive Sickle Cell center, the COVID-19 vaccine, and the data he presented at ASH.

TAK-755, a recombinant ADAMTS13, is examined for its therapeutic benefit to patients with sickle cell disease and patients with cTTP.

Of the SCD patients who contracted COVID-19, 49% of them visited the Grady Comprehensive Sickle Cell center because of a vaso-occlusive event.

New research on the preclinical product TALGlobin01 reveals the potential impact that gene therapy can have on the future of sickle cell disease treatment.

The global biopharmaceutical company released research data on rozanolixizumab and zilucoplan at the 2021 ASH annual meeting and exposition.

Shaji Kumar, MD, presents final Phase 3 data of the BELLINI trial at the ASH 2021 conference.

Among vaccinated individuals, results show a 90% lower mortality rate due to COVID-19 in the group that received a booster compared with those who did not.

Promising results show that high-flow oxygen therapy is more effective in treating patients with severe COVID-19 than conventional methods like invasive mechanical ventilation.

Investigators found about 70% of rheumatology patients had a good antibody response to the COVID-19 vaccines.

This study evaluates the likelihood that young adults with sickle cell disease or sickle cell trait will have a child or expand their family.

In this video interview, Titilope Fasipe shares a summary of her plenary presentation on sickle cell disease from the National Organization for Rare Disease summit.

Dr. Fasipe shares about her experience at the National Organization for Rare Disease Summit 2021 as the opening plenary speaker.

Investigators found that using virtual reality to reduce pain levels during operational hsyteroscopy was not effective.

A new study from the American Heart Association Scientific Sessions 2021 found that atherosclerotic cardiovascular disease risk increases with sdLDL-C levels, regardless of sex or race.

Hydroxyurea has been on the market for decades and yet it's underutilized as a treatment for sickle cell disease.

Ropeginterferon Alfa-2b-NJFT (Besremi) is approved by the FDA for the treatment of polycythemia vera regardless of a patient's treatment history.

The randomized control trial investigates the effectiveness of cognitive behavioral therapy in treating chronic pain in patients who have been using opioid therapy.

As the opening plenary speaker at the National Organization for Rare Disease summit, Dr. Fasipe shares from her unique perspective as doctor and patient of sickle cell disease.

This study looks at the risk of adverse events following immunization by comparing the safety profile of the mRNA COVID-19 vaccines to the safety profile of the influenza vaccines.

Even though COVID-19 infection disproportionately impacts minority patients, there’s no indication that vaccine intention differs depending on race in IBD patients.

This study found that compared with the general population, the prevalence of celiac disease in people with type 1 diabetes mellitus is increased.

In his lecture, The End of the Beginning: Megatrends in Gastroenterology, William Chey, MD, emphasizes the importance of a multidisciplinary integrated care approach to treating IBS.

A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

Biologic therapies show promising results of clinical remission in patients with Crohn's disease.

Dr. Aljaras talks about the importance of focusing on diet when examining irritable bowel syndrome.

In the full interview with Dr. Fasipe, she challenges healthcare professionals to step up their understanding of sickle cell disease and the complications that patients are facing when they seek help.